Biotechnology and Pharmaceuticals · eu
Getting Nerve Cells to Produce Antibodies: VectorY Raises €74.5 Million to Advance ALS Trial
The new funding will support VTx-002 through the release of final Phase I/II trial results. The therapy aims to enable sustained antibody production within the central nervous system to target abnormal TDP-43 protein; whether this can safely translate into functional improvements for patients remains a question for human studies.
Could delivering antibody-making instructions into nerve cells offer a new treatment approach for amyotrophic lateral sclerosis (ALS)? Dutch biotech company VectorY announced on November 11 that it had secured €74.5 million in financing to support its candidate therapy VTx-002 through the final analysis of results from the Phase I/II PIONEER-ALS trial, putting the concept to a more comprehensive test in humans.
The financing combines private investment and public funding. New investors include Angelini Ventures, Invest-NL and the European Investment Bank, with existing shareholders also participating. Invest-NL invested €7 million, while the European Investment Bank signed a €30 million convertible loan agreement backed by the European Commission’s InvestEU programme. The loan is included in the overall financing, with funding allocated to ALS clinical research and programmes for other neurodegenerative diseases.
VTx-002 combines gene delivery and antibody engineering: it uses a modified adeno-associated virus (AAV) as a vector to deliver genetic instructions for an antibody into cells in the central nervous system, enabling the cells to produce the antibody themselves. It is designed to recognise pathological TDP-43 aggregates. These abnormal protein accumulations are found in most patients with ALS, but whether targeting them can slow disease progression in humans is precisely what the trial must establish.
PIONEER-ALS is a multinational, multicentre, open-label dose-escalation study evaluating two doses. In September 2026, its planned enrolment was increased from 12 to 36 participants. The study focuses on safety, tolerability and preliminary efficacy. It also tracks neurofilament light chain (NfL), a marker of nerve damage; biomarkers related to the TDP-43 pathway; and clinical measures including daily functioning, respiratory capacity and survival.
Expanded enrolment can provide more data for analysis, but it does not mean efficacy has been established. According to European Biotechnology Magazine, the September expansion decision was made when no patient efficacy results were yet available, and the company has not announced an expected timeline for final results. Early open-label studies can help identify safety and efficacy signals; even if biomarkers change, those changes must be interpreted alongside patient function and disease progression. VTx-002 has not yet been approved by any regulatory authority.
The funding will also advance VTx-003, a Huntington’s disease programme that remains at the preclinical stage and targets mutant huntingtin protein. VectorY hopes to apply the same vectorized antibody platform to different diseases, but the programmes target different proteins and disease processes, and each must establish its own evidence of safety and efficacy.
### Background Context
ALS research needs to answer two questions in parallel: how to identify the disease and how to alter its course. Blood protein research is seeking diagnostic clues, while VTx-002 attempts to intervene directly against a pathological protein. For treatments of this kind, biomarkers help track responses within the body, but the ultimate question is one closer to patients’ daily lives: does the treatment actually slow the loss of muscle strength, breathing capacity and daily functioning?